MOSCOW, Dec 21 (Reuters) - Britain's AstraZeneca and
Russia's Gamaleya Institute, which developed the Sputnik V
vaccine, will sign a memorandum of intent on cooperation on
Monday, the Kremlin said.
Russia's RDIF sovereign wealth fund said this month
AstraZeneca would start clinical trials to test a combination of
its experimental COVID-19 vaccine with the Sputnik V shot to see
if this can boost the efficacy of the British drugmaker's
vaccine.
(Reporting by Dmitry Antonov; writing by Tom Balmforth; Editing
by Hugh Lawson)